Archynetys Live news trend intelligence
▲ Peaking Business

Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail

Novartis absorbs a $1.9 billion trial loss yet lifts guidance, leaving investors to weigh confidence in the Avidity deal.

By · Published October 28, 2026  11:35 UTC · Updated October 28, 2026  12:24 UTC

5sources
5articles
3velocity
+0%since first seen
1h agofirst detected
Text:
🤖 AI Dossier

Evidence dossier

Intelligence passport

53/100 Publishable
5distinct sources shown
2velocity measurements
1language editions checked
Unsupported statements were removed before publicationbrief evidence status

Measured timeline

Coverage (5)

The story so far

⚡ Executive Intelligence Takeaways Corroborated across 5 independent newsrooms
  • Velocity & Diffusion: Coverage exploded across 5 distinct news outlets with 5 published articles, achieving a live velocity of 3.
  • Primary Driver: Novartis absorbs a $1.9 billion trial loss yet lifts guidance, leaving investors to weigh confidence in the Avidity deal.
  • Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.

The timing coincides with the firm’s latest earnings window, amplifying concern over short‑term earnings versus long‑term pipeline stability. The loss stems from the del‑desiran program, a late‑stage candidate that failed to meet its endpoints, prompting a $1.9 billion write‑down reported by Fierce Pharma and FirstWord Pharma. Reuters quantified a $2.2 billion hit from the broader set of trial setbacks, yet the firm lifted its profit guidance, a move echoed by the Wall Street Journal.

Fierce Biotech noted the CEO’s continued confidence in the parallel Avidity acquisition. With guidance raised despite the write‑down, attention now turns to how the Avidity deal will offset the shortfall and whether upcoming trial data can restore confidence. Upcoming regulatory filings and early results from other pipeline candidates will indicate whether the optimistic revenue target is sustainable.

Stakeholders watch for the next earnings release to gauge the financial impact of the setbacks.

Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (78% supported) Updated 1h ago.

The obvious questions

What financial impact did the del‑desiran failure have on Novartis?

Novartis recorded a $1.9 billion write‑down for the del‑desiran failure, and Reuters reported a total $2.2 billion hit from related trial setbacks.

How did Novartis adjust its profit guidance after the setbacks?

Despite the write‑downs, Novartis lifted its annual profit guidance, as noted by the Wall Street Journal.

What is the company’s stance on the Avidity deal after the loss?

The CEO expressed continued confidence in the Avidity partnership, according to Fierce Biotech.

The coverage curve

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

📊 AUDIENCE & LONGEVITY PULSE

How do you expect this trend to evolve over the next 24 hours?

Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.

Select an assessment to vote. Verified Reader Intelligence

Topics

Novartis del-desiran Avidity WSJ Reuters

Related trends

Open prediction lab

Can you beat the machine?

Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.

Make a prediction →